Genomic data is being integrated into clinical trials—sometimes not so successfully, and sometimes very, very successfully.
Cancer therapies dominate 40% of the global clinical pipeline, and the field of oncology is leading the precision medicine revolution.
The world's oncology pipeline is rapidly growing, with nearly 40% of the global clinical pipeline focused on immuno-oncology.
Challenge #1: An Abundance of Biomarker Data
Today’s guest post is from Reinhard von Roemeling, board certified oncologist and former SVP of global oncology at EMD-Serono/Merck KGaA.